− Ebbers named Executive Vice President and General Manager, Dermatology
− Tyson named Vice President,
Mr. Ebbers will assume the new role of EVP immediately and will continue
to lead the strategy and execution of the launch of Pulse Bioscience’s
CellFX System. Mr. Ebbers joined the Company in
“In a short period of time, Ed has proven to be an exceptional leader with a deep understanding and strong relationships in the dermatology field. He is uniquely qualified to lead the commercialization of our CellFX System as we build an exciting business in dermatology,” said Darrin Uecker, Pulse Biosciences’ President and Chief Executive Officer.
Mr. Tyson joins
“I am delighted to welcome Bobby to the Pulse team as we create a successful sales force to introduce the CellFX System. Bobby has a stellar reputation among physicians and peers that reflects his strong commitment to customer relationships, ongoing service and practice growth. We are confident that Pulse will benefit greatly from having two strong leaders like Ed and Bobby spearheading our first product launch,” concluded Uecker.
Procedures conducted with the novel CellFX system continue to demonstrate strong positive results in clinical studies clearing benign lesions, including seborrheic keratosis and sebaceous hyperplasia. Encouraging data from ongoing immunotherapy studies of the CellFX procedure in human Basal Cell Carcinoma, combined with a growing pipeline of potential indications, have also been recently reported by the Company.
“I am honored to work with an innovative team committed to evolving an exceptional mechanism of action into a first-rate, new treatment category that will bring high value for our customers and stakeholders. It’s exciting to reunite with Bobby to drive CellFX commercialization and business growth for Pulse Biosciences,” said Ebbers.
Tyson commented: “I look forward to once again working with Ed and the
Pulse Biosciences is a novel medical therapy company bringing to market its proprietary CellFX™ System. The Company’s novel CellFX System provides a precise, non-thermal delivery of nanosecond duration energy pulses that impact cells in treated tissue while sparing acellular tissue. This unique mechanism of action disrupts the functions of internal cell structures while maintaining the outer cell membrane, initiating a cascade of events within the cell that results in regulated cell death. The novel characteristics of the Company’s CellFX System has the potential to significantly benefit patients across multiple medical applications, including dermatology, the Company’s first planned commercial application. In pre-clinical studies, NPS has demonstrated an ability to induce immunogenic cell death in several cancer cell lines. The Company believes its NPS platform technology may play a role in immuno-oncology as a focal tumor treatment that can initiate an adaptive immune response. More information can be found at www.pulsebiosciences.com.
All statements in this press release that are not historical are
forward-looking statements, including, among other things, statements
relating to Pulse Biosciences’ expectations regarding commercialization
of the CellFX system, regulatory clearance and the timing of FDA filings
or approvals, the mechanism of action of NPS and CellFX treatments,
current and planned future clinical studies, other matters related to
its pipeline of product candidates, future financial performance and
business strategies and other future events. These statements are not
historical facts but rather are based on Pulse Biosciences’ current
expectations, estimates, and projections regarding Pulse Biosciences’
business, operations and other similar or related factors. Words such as
“may,” “will,” “could,” “would,” “should,” “anticipate,” “predict,”
“potential,” “continue,” “expects,” “intends,” “plans,” “projects,”
“believes,” “estimates,” and other similar or related expressions are
used to identify these forward-looking statements, although not all
forward-looking statements contain these words. You should not place
undue reliance on forward-looking statements because they involve known
and unknown risks, uncertainties, and assumptions that are difficult or
impossible to predict and, in some cases, beyond Pulse Biosciences’
control. Actual results may differ materially from those in the
forward-looking statements as a result of a number of factors, including
those described in Pulse Biosciences’ filings with the
CAUTION: Pulse Biosciences’ CellFX System and Nano-Pulse Stimulation (NPS) are investigational use only.
Sr. Vice President and Chief Financial Officer
Gitanjali Jain Ogawa
Nadine D. Tosk, 504-453-8344